Log In
BCIQ
Print this Print this
 

LIPO-202

  Manage Alerts
Collapse Summary General Information
Company Neothetics Inc.
DescriptionSubcutaneous formulation of salmeterol xinafoate, a long-acting adrenergic receptor beta 2 agonist (LABA)
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationBody Fat
Indication DetailsReduce subcutaneous abdominal fat; Reduce submental bulging due to subcutaneous fat
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today